As we find that commercially available antibodies for TLR4 and SLAMF1 have low specificity in immunoblotting, efficient silencing was confirmed by significantly reducing TLR4 and SLAMF1 mRNA levels at all tested infection time points, as well as reducing LPS-induced TNF and IFNB1 in siTLR4-treated MDMs (Supplementary Figure S4). The gene discussed is SLAMF1; the disease is infection.